PTHS
Pelthos Therapeutics Inc.
Healthcare — Biotechnology
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Price History
Fundamentals
| Market Cap | $97.32M |
| P/E Ratio (TTM) | - |
| Forward P/E | -13.18 |
| EPS (TTM) | $-22.92 |
| Dividend Yield | - |
| Profit Margin | -186.23% |
| Revenue Growth | - |
| ROE | -333.84% |
| Debt/Equity | 150.79 |
| Recommendation | Strong Buy 1.1 |
| Analyst Target | $57.71 |
| Analysts | 7 |
| Next Earnings | Aug 13, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 52.3 |
| Beta | 3.20 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $54.29 |
| 52-Week Low | $13.88 |
| 50-Day Avg | $26.48 |
| 200-Day Avg | $26.51 |
| Avg Volume | 21.8K |
| Volume | 31.6K |
Performance Analysis
NEUTRALPTHS presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:27 UTC
Back to Screener Export Report